SCYNEXIS EBITDA 2013-2025 | SCYX

SCYNEXIS ebitda from 2013 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

SCYNEXIS EBITDA 2013-2025 | SCYX

SCYNEXIS ebitda from 2013 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$71.7B
Zoetis (ZTS)$69.5B
Daiichi Sankyo, - (DSNKY)$49.8B
Takeda Pharmaceutical (TAK)$49.3B
BeOne Medicines - (ONC)$33.9B
Sandoz Group AG (SDZNY)$26.7B
Summit Therapeutics (SMMT)$19.2B
Merck (MKKGY)$16.8B
Shionogi (SGIOY)$15.2B
United Therapeutics (UTHR)$13.8B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.2B
IPSEN (IPSEY)$11.2B
Eisai (ESAIY)$9.3B
Madrigal Pharmaceuticals (MDGL)$8.7B
Corcept Therapeutics (CORT)$7.4B
Grifols, S.A (GRFS)$7B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Ono Pharmaceutical (OPHLF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.7B
NewAmsterdam Pharma (NAMS)$2.7B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B
Endo (NDOI)$1.8B